• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球可用的COVID-19候选疫苗和疫苗开发平台。

COVID-19 vaccine candidates and vaccine development platforms available worldwide.

作者信息

Duman Nilgun, ALzaidi Zahraa, Aynekin Busra, Taskin Duygu, Demirors Busra, Yildirim Abdulbaki, Sahin Izem Olcay, Bilgili Faik, Turanli Eda Tahir, Beccari Tommaso, Bertelli Matteo, Dundar Munis

机构信息

Department of Medical Genetics, Dragos Hospital Istanbul, Bezmialem Vakif University, Istanbul, 34854, Turkey.

Department of Biotechnology, Faculty of Applied Science, Cukurova University, Adana, 01380, Turkey.

出版信息

J Pharm Anal. 2021 Dec;11(6):675-682. doi: 10.1016/j.jpha.2021.09.004. Epub 2021 Sep 14.

DOI:10.1016/j.jpha.2021.09.004
PMID:34540318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8437828/
Abstract

The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.

摘要

由2019年首次出现的冠状病毒在全球传播引发的大流行被命名为冠状病毒病19(COVID-19)。据世界卫生组织称,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发的大流行已导致超过450万人死亡。2021年9月的COVID-19数据仪表盘。除了野生型,其他变异在疫情早期就已成功传播,尽管直到2020年3月才被发现。SARS-CoV-2遗传物质的改变,如突变和重组,能够改变病毒的生命周期,以及传播性、细胞嗜性和症状严重程度。向人群引入新型疫苗涉及多个过程,包括疫苗生产、临床前研究、食品药品监督管理局的许可或认证、加工和营销。许多公共和私人团体采用多种策略,如RNA、DNA、蛋白质和病毒载体疫苗,开发了COVID-19候选疫苗。本综述全面检索了近期在线数据库,纳入了关于SARS-CoV-2独特特征以及相关发病率和死亡率的最新证据,以生成有关COVID-19更新版本及其对疾病症状和疫苗开发影响的有用知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/0ce8038e16e0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/59e38065a750/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/21731b21e2cc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/67d8bc73762f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/f4b534f32b2b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/daa923b7101d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/d1e303962f4b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/0ce8038e16e0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/59e38065a750/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/21731b21e2cc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/67d8bc73762f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/f4b534f32b2b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/daa923b7101d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/d1e303962f4b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30b/8740370/0ce8038e16e0/gr6.jpg

相似文献

1
COVID-19 vaccine candidates and vaccine development platforms available worldwide.全球可用的COVID-19候选疫苗和疫苗开发平台。
J Pharm Anal. 2021 Dec;11(6):675-682. doi: 10.1016/j.jpha.2021.09.004. Epub 2021 Sep 14.
2
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
3
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
4
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告:评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
5
Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).关于开发严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗的观点。
Hum Vaccin Immunother. 2020 Oct 2;16(10):2366-2369. doi: 10.1080/21645515.2020.1787064. Epub 2020 Sep 22.
6
Viral vector and nucleic acid vaccines against COVID-19: A narrative review.针对新型冠状病毒肺炎的病毒载体疫苗和核酸疫苗:一篇综述。
Front Microbiol. 2022 Aug 31;13:984536. doi: 10.3389/fmicb.2022.984536. eCollection 2022.
7
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
8
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
9
SARS-CoV-2 vaccine candidates in rapid development.正在快速开发的 SARS-CoV-2 疫苗候选物。
Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.
10
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.关于在疫情爆发情况下治疗新型冠状病毒(SARS-CoV-2)的新兴治疗和预防策略的循证系统评价。
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.

引用本文的文献

1
Deciphering the host genetic factors conferring susceptibility to severe COVID-19 using exome sequencing.利用外显子组测序解析导致严重新型冠状病毒肺炎易感性的宿主遗传因素。
Genes Immun. 2024 Feb;25(1):14-42. doi: 10.1038/s41435-023-00232-9. Epub 2023 Dec 20.
2
Towards the development of an epitope-focused vaccine for SARS-CoV-2.针对 SARS-CoV-2 的表位聚焦疫苗的开发。
Vaccine. 2022 Oct 26;40(45):6489-6498. doi: 10.1016/j.vaccine.2022.09.059. Epub 2022 Sep 27.
3
Misdiagnosis of Reactive Lymphadenopathy Remotely After COVID-19 Vaccination: A Case Report and Literature Review.

本文引用的文献

1
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.与关注的阿尔法(B.1.1.7)变体相比,感染新冠病毒德尔塔(B.1.617.2)变体的住院和急诊就诊风险:一项队列研究。
Lancet Infect Dis. 2022 Jan;22(1):35-42. doi: 10.1016/S1473-3099(21)00475-8. Epub 2021 Aug 27.
2
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
3
The Age Structure, Stringency Policy, Income, and Spread of Coronavirus Disease 2019: Evidence From 209 Countries.
新冠疫苗接种后反应性淋巴结病的远程误诊:一例报告及文献综述
Front Immunol. 2022 Jun 23;13:875637. doi: 10.3389/fimmu.2022.875637. eCollection 2022.
4
Promising Antiviral Activity of Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study.体内小鼠研究支持植物化学物质对严重急性呼吸综合征冠状病毒2具有抗病毒活性
Pharmaceuticals (Basel). 2021 Dec 16;14(12):1313. doi: 10.3390/ph14121313.
2019年冠状病毒病的年龄结构、严格政策、收入与传播:来自209个国家的证据
Front Psychol. 2021 Feb 12;11:632192. doi: 10.3389/fpsyg.2020.632192. eCollection 2020.
4
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)疫苗策略:对3期候选疫苗的全面综述
NPJ Vaccines. 2021 Feb 22;6(1):28. doi: 10.1038/s41541-021-00292-w.
5
Emergence of a Novel SARS-CoV-2 Variant in Southern California.新型 SARS-CoV-2 变异株在南加州出现。
JAMA. 2021 Apr 6;325(13):1324-1326. doi: 10.1001/jama.2021.1612.
6
Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.住院 COVID-19 患者中针对 SARS-CoV-2 的抗体的时间发展和中和潜力:一项观察性队列研究。
PLoS One. 2021 Jan 26;16(1):e0245382. doi: 10.1371/journal.pone.0245382. eCollection 2021.
7
Human SARS CoV-2 spike protein mutations.人类严重急性呼吸系统综合征冠状病毒 2 刺突蛋白突变。
Proteins. 2021 May;89(5):569-576. doi: 10.1002/prot.26042. Epub 2021 Jan 17.
8
New variant of SARS-CoV-2 in UK causes surge of COVID-19.英国出现的新冠病毒新变种导致新冠肺炎病例激增。
Lancet Respir Med. 2021 Feb;9(2):e20-e21. doi: 10.1016/S2213-2600(21)00005-9. Epub 2021 Jan 5.
9
DNA vaccines against COVID-19: Perspectives and challenges.针对 COVID-19 的 DNA 疫苗:观点与挑战。
Life Sci. 2021 Feb 15;267:118919. doi: 10.1016/j.lfs.2020.118919. Epub 2020 Dec 19.
10
Coronavirus vaccine development: from SARS and MERS to COVID-19.冠状病毒疫苗的研发:从 SARS 和 MERS 到 COVID-19。
J Biomed Sci. 2020 Dec 20;27(1):104. doi: 10.1186/s12929-020-00695-2.